Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we...

Full description

Bibliographic Details
Main Authors: Husain Yar Khan, James Ge, Misako Nagasaka, Amro Aboukameel, Gabriel Mpilla, Irfana Muqbil, Mark Szlaczky, Mahmoud Chaker, Erkan Baloglu, Yosef Landesman, Ramzi M. Mohammad, Asfar S. Azmi, Ammar Sukari
Format: Article
Language:English
Published: MDPI AG 2019-12-01
Series:International Journal of Molecular Sciences
Subjects:
thyroid cancer
lenvatinib
therapy resistance
selinexor
pak4 inhibitor
selective inhibitors of nuclear export
Online Access:https://www.mdpi.com/1422-0067/21/1/237

Internet

https://www.mdpi.com/1422-0067/21/1/237

Similar Items